Equities Analysts Set Expectations for Repligen Q3 Earnings

Key Points

• William Blair raised their Q3 2025 earnings estimates for Repligen from $0.40 to $0.41 per share, while the consensus estimate for the full-year earnings is $1.72 per share.
• Repligen reported Q2 earnings of $0.37 per share, which missed analysts' estimates of $0.40, although they achieved revenues of $182.37 million, exceeding expectations of $174.62 million.
• Currently, Repligen has an average rating of "Moderate Buy" among analysts, with a target price averaging $169.45 per share amidst various ratings changes by leading research firms.

Repligen Corporation (NASDAQ:RGEN - Free Report) - Investment analysts at William Blair raised their Q3 2025 earnings estimates for shares of Repligen in a report released on Tuesday, July 29th. William Blair analyst M. Larew now anticipates that the biotechnology company will earn $0.41 per share for the quarter, up from their prior forecast of $0.40. The consensus estimate for Repligen's current full-year earnings is $1.72 per share. William Blair also issued estimates for Repligen's Q4 2025 earnings at $0.52 EPS, Q2 2026 earnings at $0.59 EPS and FY2026 earnings at $2.38 EPS.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The firm had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.65%. Repligen's revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.40 EPS.

Several other equities research analysts have also recently weighed in on the company. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective for the company in a report on Tuesday, April 29th. Barclays started coverage on Repligen in a report on Tuesday, June 24th. They set an "overweight" rating and a $150.00 target price for the company. JPMorgan Chase & Co. cut their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Stephens upgraded shares of Repligen to an "overweight" rating and set a $160.00 price objective for the company in a report on Tuesday, July 22nd. Finally, Canaccord Genuity Group dropped their target price on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Repligen presently has an average rating of "Moderate Buy" and an average price target of $169.45.

Repligen Stock Down 4.7%

NASDAQ RGEN opened at $117.07 on Friday. Repligen has a 1 year low of $102.96 and a 1 year high of $182.52. The stock has a market capitalization of $6.58 billion, a PE ratio of -468.26, a PEG ratio of 2.27 and a beta of 1.11. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.79 and a quick ratio of 5.79. The business's 50-day moving average is $123.46 and its 200 day moving average is $136.78.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of RGEN. Raiffeisen Bank International AG purchased a new stake in Repligen in the fourth quarter worth about $29,000. Twin Tree Management LP bought a new stake in shares of Repligen in the 1st quarter worth approximately $29,000. Itau Unibanco Holding S.A. purchased a new stake in shares of Repligen in the 4th quarter worth approximately $40,000. Signaturefd LLC grew its stake in shares of Repligen by 65.3% in the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock worth $41,000 after buying an additional 128 shares during the last quarter. Finally, Center for Financial Planning Inc. increased its position in Repligen by 110.3% during the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock valued at $47,000 after buying an additional 193 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.